汇宇制药：公司产品注射用紫杉醇(白蛋白结合型)获得多国境外上市许可

Core Viewpoint - Seacross Pharma (Europe) Ltd., a subsidiary of Huayu Pharmaceutical, has received marketing authorization for its injectable paclitaxel (albumin-bound) from regulatory authorities in the Netherlands, Ireland, Finland, and Sweden, indicating a significant advancement in the company's product offerings for treating metastatic breast cancer patients [1] Group 1 - The product, injectable paclitaxel (albumin-bound), is primarily indicated as a monotherapy for adult patients with metastatic breast cancer who have not responded to first-line treatment and for whom standard anthracycline-based therapy is not suitable [1]